ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
ICON to Offer At-Home Clinical Trials following Symphony Purchase
ICON boosts its hybrid clinical trial and site support services with the acquisition of Symphony Clinical Research, a provider of in-home and alternate site services.
Alzheimer’s in Clinical Trials – Is There a Way Out of Ongoing Failures?
A thought leadership article authored by Peter Scheuler, exploring how the series of failures in Alzheimer’s disease research has provided insights into the disease pathology, study methodologies and - as a consequence – in the design of future development programmes for anti-Alzheimer medications.
Validating Value Data: AI & Outcomes
The application of AI and machine learning in establishing a treatment’s value proposition is still a relatively new concept in pharma. Learn more in this article.
Patient Voices in the Industry
Will Maier and Kelly Franchetti discuss orphan drugs and patients' role in clinical trials as demand in the market increases.
Can Digital Technologies and AI improve R&D productivity enough to restore ROI?
A thought leadership article authored by Tom O’Leary, exploring what can be done to help ensure return on investment in clinical trials.
Patient-Centric Approach to Improve the Patient Experience
Joyce Moore, Director Patient Recruitment Services, discusses the changing dynamics of the patient journey in engaging potential patients.
A World of Possibilities
A thought leadership article authored by Stephanie Merrigan on the urgent need for more comprehensive and accessible educational tools to enhance patient engagement and retention.
The Blockchain Movement
Ronan Fox, VP, Applied Digital Solutions discusses blockchain in clinical trials, particularly as an enabler of virtual trials.
Ioannis Katsoulis, Axel Svedbom, Larushka Mellor and Örjan Åkerborg consider trends and strategies to drive uptake of biosimilars in the UK.
The Path to Successful HTA Submissions
Manpreet Sidhu discusses the factors that are key to success in achieving favourable HTA reviews around the world in this Pharmafocus article.